Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: A latent transition analysis of the CIDUS 3/DUIT study

AIDS and Behavior

Volumn 17, Issue 6, 2013, Pages 2075-2083

  MacKesy Amiti, Mary E ^a   Finnegan, Lorna ^a   Ouellet, Lawrence J ^a   Golub, Elizabeth T ^b   Hagan, Holly ^c   Hudson, Sharon M ^d   Latka, Mary H ^e   Garfein, Richard S ^f  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^d Health Research Association   (United States)

^e AURUM INSTITUTE   (South Africa)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HCV; HIV; Injection drug use; Intervention; Latent class analysis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO HEALTH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABUSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METHODOLOGY; PATIENT EDUCATION; PEER GROUP; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICS; SUBSTANCE ABUSE; UNITED STATES;

ADOLESCENT; ADULT; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; NEEDLE SHARING; PATIENT EDUCATION AS TOPIC; PEER GROUP; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; YOUNG ADULT;

EID: 84879007128     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0373-0     Document Type: Article

References (50)

1. Santibanez S, Garfein R, Swartzendruber A, Purcell D, Paxton L, Greenberg A. Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. J Urban Health. 2006;83(1):86-100.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. Vol. 19. Atlanta, GA: U.S. Department of Health and Human Services; 2009. Available from http://www.cdc.gov/hiv/topics/surveillance/resources/reports.
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436-41.
4. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of Hepatitis B and C. Washington DC.: The National Academies Press; 2010.
5. Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis. 2000;182(6):1588-94.
6. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, et al. Prevalence of Hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46(12):1852-8.
7. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86(5):655-61.
8. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149(3):203-13.
9. Tibbs CJ. Methods of transmission of hepatitis C. J Viral Hepat. 1995;2(3):113-9.
10. Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML, Montaner JSG, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59-65.
11. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645-53.
12. Thiede H, Hagan H, Campbell JV, Strathdee SA, Bailey SL, Hudson SM, et al. Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U.S. cities. Drug Alcohol Depend. 2007;91(Suppl. 1):S39-47.
13. Centers for Disease Control and Prevention. HIV-associated behaviors among injecting drug users - 23 cities, United States, May 2005-February 2006. Morb Mortal Wkl Rep. 2009;58(13):329-32.
14. Bluthenthal RN, Anderson R, Flynn NM, Kral AH. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend. 2007;89(2-3):214-22.
15. Huo D, Ouellet LJ. Needle exchange and sexual risk behaviors among a cohort of injection drug users in Chicago, Illinois. Sex Transm Dis. 2009;36(1):35-40.
16. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS. 2005;19(Suppl. 3):S20-5.
17. Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. 1998;113(Suppl. 1):19-30.
18. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6-7):777-813.
19. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15(11):1329-41.
20. Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14(5):605-11.
21. Marshall BDL, Wood E. Toward a comprehensive approach to HIV prevention for people who use drugs. J Acquir Immune Defic Syndr. 2010;55(Suppl. 1):S23-6.
22. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59(1):17-31.
23. Booth RE, Kwiatkowski CF, Stephens RC. Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. J Psychoact Drugs. 1998;30(3):269-78.
24. Gibson DR, Lovelle-Drache J, Young M, Hudes ES, Sorensen JL. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: final results of randomized trials of counseling with and without HIV testing. AIDS Behav. 1999;3(1):3-12.
25. Meader N, Ryan L, Des Jarlais DC, Pilling S. Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev. 2010; (1). doi: 10.1002/14651858.CD007192. pub2.
26. Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy. 2012;23(3):176-84.
27. Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22(4):332-9.
28. Latka MH, Hagan H, Kapadia F, Golub ET, Bonner S, Campbell JV, et al. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Am J Public Health. 2008;98(5):853-61.
29. Tobin KE, Kuramoto SJ, Davey-Rothwell MA, Latkin CA. The STEP into Action study: a peer-based, personal risk network-focused HIV prevention intervention with injection drug users in Baltimore, Maryland. Addiction. 2011;106(2):366-75.
30. Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007;21(14):1923-32.
31. Mackesy-Amiti ME, Ouellet LJ, Golub ET, Hudson S, Hagan H, Garfein RS. Predictors and correlates of reduced frequency or cessation of injection drug use during a randomized HIV prevention intervention trial. Addiction. 2011;106(3):601-8.
32. Muthén B. Latent variable modeling in heterogeneous populations. Psychometrika. 1989;54(4):557-85.
33. McCutcheon AL. Latent class analysis. Newbury Park: Sage; 1987.
34. Collins LM, Wugalter SE. Latent class models for stage-sequential dynamic latent-variables. Multivar Behav Res. 1992;27(1):131-57.
35. Lanza ST, Flaherty BP, Collins LM. Latent class and latent transition analysis. Handbook of psychology. Hoboken: Wiley; 2003.
36. Collins LM, Graham JW, Rousculp SS, Fidler PL, Pan J, Hansen WB. Latent transition analysis and how it can address prevention research questions. In: Collins LM, Seitz LA, editors. Advances in data analysis for prevention intervention research. Rockville: U.S. Department of Health and Human Services; 1994.
37. Garfein RS, Swartzendruber A, Ouellet LJ, Kapadia F, Hudson SM, Thiede H, et al. Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend. 2007;91(Suppl. 1):S4-17.
38. Purcell DW, Garfein RS, Latka MH, Thiede H, Hudson S, Bonner S, et al. Development, description, and acceptability of a small-group, behavioral intervention to prevent HIV and hepatitis C virus infections among young adult injection drug users. Drug Alcohol Depend. 2007;91(Suppl. 1):S73-80.
39. MPlus [computer program]. Muthén & Muthén; Ver. 6.1, 2010.
40. Satorra A, Bentler PM. A scaled difference Chi-square test statistic for moment structure analysis. UCLA Department of Statistics, 1999. Available from http://preprints.stat.ucla.edu.
41. Dickson-Gomez J, Weeks MR, Convey M, Jianghong L. Social psychological dynamics of enhanced HIV risk reduction among peer interventionists. J Community Psychol. 2011;39(4):369-89.
42. Fisher JD, Misovich S. Social influence and AIDS-preventive behavior. In: Edwards J, Tindale RS, Heath L, Posavac EJ, editors. Social influence processes and prevention. New York: Plenum Press; 1990. p. 39-70.
43. Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL, Madray H, Mills RJ, et al. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Rep. 1998;113(Suppl. 1):42-57.
44. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive behaviors. Am Psychol. 1992;47(9):1102-14.
45. Prochaska JO, Redding CA, Harlow LL, Rossi JS, Velicer WF. The transtheoretical model of change and HIV prevention: a review. Health Educ Behav. 1994;21(4):471-86.
46. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. The Lancet. 2010;376(9737):285-301.
47. Huo D, Bailey SL, Garfein RS, Ouellet LJ. Changes in the sharing of drug injection equipment among street-recruited injection drug users in Chicago, Illinois, 1994-1996. Subst Use Misuse. 2005;40(1):63-76.
48. Thorpe LE, Bailey SL, Huo D, Monterroso ER, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr. 2001;27(1):71-8.
49. Sherman SG, Latkin CA, Gielen AC. Social factors related to syringe sharing among injecting partners: a focus on gender. Subst Use Misuse. 2001;36(14):2113-36.
50. Mandell W, Vlahov D, Latkin C, Oziemkowska M, Cohn S. Correlates of needle sharing among injection-drug users. Am J Public Health. 1994;84(6):920-3.